152 related articles for article (PubMed ID: 37504341)
21. Enteral lorlatinib after alectinib as a treatment option in anaplastic lymphoma kinase-positive non-small cell lung cancer with triple problems: carcinomatous meningitis, poor performance status, and dysphagia-a case report.
Sasaki K; Yokota Y; Isojima T; Fujii M; Hasui K; Chen Y; Saito K; Takahata T; Kindaichi S; Sato A
Respirol Case Rep; 2021 Jul; 9(7):e00796. PubMed ID: 34123384
[TBL] [Abstract][Full Text] [Related]
22. Economic burden in patients with anaplastic lymphoma kinase (
Wu Y; Ren K; Wan Y; Lin HM
J Oncol Pharm Pract; 2023 Sep; 29(6):1418-1427. PubMed ID: 36131505
[TBL] [Abstract][Full Text] [Related]
23. Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results.
Goldsmith KC; Park JR; Kayser K; Malvar J; Chi YY; Groshen SG; Villablanca JG; Krytska K; Lai LM; Acharya PT; Goodarzian F; Pawel B; Shimada H; Ghazarian S; States L; Marshall L; Chesler L; Granger M; Desai AV; Mody R; Morgenstern DA; Shusterman S; Macy ME; Pinto N; Schleiermacher G; Vo K; Thurm HC; Chen J; Liyanage M; Peltz G; Matthay KK; Berko ER; Maris JM; Marachelian A; Mossé YP
Nat Med; 2023 May; 29(5):1092-1102. PubMed ID: 37012551
[TBL] [Abstract][Full Text] [Related]
24. Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma.
Berko ER; Witek GM; Matkar S; Petrova ZO; Wu MA; Smith CM; Daniels A; Kalna J; Kennedy A; Gostuski I; Casey C; Krytska K; Gerelus M; Pavlick D; Ghazarian S; Park JR; Marachelian A; Maris JM; Goldsmith KC; Radhakrishnan R; Lemmon MA; Mossé YP
Nat Commun; 2023 May; 14(1):2601. PubMed ID: 37147298
[TBL] [Abstract][Full Text] [Related]
25. ISOLATED VITREOUS METASTASIS IN A PATIENT WITH AN ANAPLASTIC LYMPHOMA KINASE-POSITIVE LUNG CANCER TREATED WITH LORLATINIB.
Suzani M; Benatti E; Ceola S; Coppola M
Retin Cases Brief Rep; 2024 Mar; 18(2):194-198. PubMed ID: 36228188
[TBL] [Abstract][Full Text] [Related]
26. Enteral lorlatinib after immune hyperprogression as a treatment option for anaplastic lymphoma kinase‑positive non‑small cell lung cancer: A case report.
Wang H; Wu Z; Shi G; Zhou J; Xiao Z
Oncol Lett; 2023 Dec; 26(6):526. PubMed ID: 38020308
[TBL] [Abstract][Full Text] [Related]
27. Pathological complete response to neoadjuvant lorlatinib in a patient with unresectable ALK-Positive locally advanced non-small cell lung cancer: A case report.
Chen R; Zhao L; Zhang J; Guo L; Chen Z; Pan X; Chen W
Heliyon; 2023 Nov; 9(11):e21582. PubMed ID: 38034719
[TBL] [Abstract][Full Text] [Related]
28. Safety of lorlatinib in ALK-positive non-small-cell lung cancer and management of central nervous system adverse events.
Kilickap S; Ak S; Dursun OU; Sendur MA; Karadurmus N; Demirci U
Future Oncol; 2023 Sep; 19(29):2003-2012. PubMed ID: 37449387
[TBL] [Abstract][Full Text] [Related]
29. Diagnosis and Treatment of Advanced ALK Rearrangement-Positive Non-Small-Cell Lung Cancer in Portugal: Results of a National Questionnaire.
Figueiredo A; Rodrigues A; Gaspar C; Felizardo M
Drugs Real World Outcomes; 2023 Dec; 10(4):545-555. PubMed ID: 37787868
[TBL] [Abstract][Full Text] [Related]
30. An advanced NSCLC patient with
Li H; Liu J; Lan S; Zhong R; Cui Y; Christopoulos P; Schenk EL; Sasaki T; Cheng Y
Transl Lung Cancer Res; 2023 Dec; 12(12):2538-2549. PubMed ID: 38205210
[TBL] [Abstract][Full Text] [Related]
31. Feasibility and Challenges for Sequential Treatments in ALK-Rearranged Non-Small-Cell Lung Cancer.
Elsayed M; Bozorgmehr F; Kazdal D; Volckmar AL; Sültmann H; Fischer JR; Kriegsmann M; Stenzinger A; Thomas M; Christopoulos P
Front Oncol; 2021; 11():670483. PubMed ID: 33959513
[TBL] [Abstract][Full Text] [Related]
32. Overcoming Central β-Sheet #6 (Cβ6)
Lee ATM; Ou SI
Lung Cancer (Auckl); 2024; 15():19-27. PubMed ID: 38433979
[TBL] [Abstract][Full Text] [Related]
33. Recent Advances in the Management of Adverse Events Associated with Lorlatinib.
Liao D; Zhang J; Yan T; Chen S; Li W; Shangguan D; She Z
Onco Targets Ther; 2023; 16():731-738. PubMed ID: 37694103
[TBL] [Abstract][Full Text] [Related]
34. A computational examination of the therapeutic advantages of fourth-generation ALK inhibitors TPX-0131 and repotrectinib over third-generation lorlatinib for NSCLC with ALK F1174C/L/V mutations.
Balasundaram A; Doss GPC
Front Mol Biosci; 2023; 10():1306046. PubMed ID: 38274094
[No Abstract] [Full Text] [Related]
35. Effective treatment of advanced lung adenocarcinoma with paraneoplastic leukemoid reaction with Lorlatinib: a case report.
Niu R; Zhang Y; Pang J; Zhou Q; Lei Y; Du Y
Front Oncol; 2024; 14():1341233. PubMed ID: 38344203
[TBL] [Abstract][Full Text] [Related]
36. Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced
Thummalapalli R; Choudhury NJ; Ehrich F; Beardslee T; Brazel D; Zhang SS; Merchant S; Chen MF; Heller G; Ramalingam SS; Ou SI; Mileham KF; Riely GJ
JTO Clin Res Rep; 2023 Aug; 4(8):100546. PubMed ID: 37644967
[TBL] [Abstract][Full Text] [Related]
37. Deciphering the Mechanism of Gilteritinib Overcoming Lorlatinib Resistance to the Double Mutant I1171N/F1174I in Anaplastic Lymphoma Kinase.
Liang S; Wang Q; Qi X; Liu Y; Li G; Lu S; Mou L; Chen X
Front Cell Dev Biol; 2021; 9():808864. PubMed ID: 35004700
[TBL] [Abstract][Full Text] [Related]
38. Lorlatinib After Alectinib-Induced Pneumonitis: A Case Report.
Fletcher JA; Mullally WJ; Ladwa R; O'Byrne KJ
JTO Clin Res Rep; 2024 Feb; 5(2):100591. PubMed ID: 38357093
[No Abstract] [Full Text] [Related]
39. Bilateral optic neuropathy associated with lorlatinib monotherapy for ALK-positive metastatic lung adenocarcinoma.
Kong AW; Engelmann AR; Hosseini M; Bonelli L
Am J Ophthalmol Case Rep; 2024 Jun; 34():102063. PubMed ID: 38707952
[TBL] [Abstract][Full Text] [Related]
40. Navigating resistance to ALK inhibitors in the lorlatinib era: a comprehensive perspective on NSCLC.
Gemelli M; Albini A; Catalano G; Incarbone M; Cannone M; Balladore E; Ricotta R; Pelosi G
Expert Rev Anticancer Ther; 2024 Apr; ():1-15. PubMed ID: 38630549
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
